Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor with sustained multi-phasic release profiles and methods of use
The present disclosure is directed formulations, delivery systems and/or methods of use that have a novel a sustained release multi-phasic concentration pattern that may be used, among other things, for reducing mammographic breast density and/or breast stiffness in warm-blooded animals. For example, the formulation may comprise: the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor to a subject that provides a sustained release multi-phasic concentration pattern in the blood of the subject over time as measured by serum concentration for the androgen and plasma concentration for the aromatase inhibitor and improves, among other things, breast tissue stabilization and/or increases of the levels of androgen receptor expression. The present disclosure is also directed to the use of an effective amount of an androgenic agent in combination with an effective amount of an aromatase inhibitor for the prophylaxis or treatment of autoimmune inflammatory mastitis (AIM) in a patient in 15 need thereof. Autoimmune inflammatory mastitis includes the conditions of idiopathic inflammatory macromastia, plasma cell mastitis, granulomatous mastitis.
1. A method for the treatment of autoimmune inflammatory mastitis in a patient in need thereof, comprising administering to the patient i) an effective amount of an androgenic agent in combination with ii) an effective amount of an aromatase inhibitor;
wherein the pharmaceutical formulation provides a sustained release multi-phasic concentration pattern in the blood of the patient over time as measured by serum concentration for the androgen and plasma concentration for the aromatase inhibitor.
2. The method of claim 1 , wherein the androgenic agent and the aromatase inhibitor are administered to the patient in the same pharmaceutical formulation or in different pharmaceutical formulations to one another.
3. The method of claim 2 , wherein the androgenic agent and the aromatase inhibitor are administered to the patient in the same pharmaceutical formulation.
4. The method of claim 2 , wherein the androgenic agent and the aromatase inhibitor are administered to the patient in a separate pharmaceutical formulation to one another.
5. The method of claim 3 , wherein the pharmaceutical formulation is a sustained-release pharmaceutical formulation.
6. The method of claim 5 , wherein the pharmaceutical formulation is in a solid dosage form and is delivered to the patient subcutaneously.
7. The method of claim 6 , wherein the pharmaceutical formulation is in the form of a pellet.
8. The method of claim 3 , wherein the androgenic agent and the aromatase inhibitor are delivered to the patient subcutaneously.
9. The method of claim 1 , wherein the autoimmune inflammatory mastitis is selected from the group consisting of idiopathic inflammatory macromastia, plasma cell mastitis, granulomatous mastitis, and combinations of the foregoing.
10. The method of claim 1 , wherein the androgenic agent is a testosterone or a pharmaceutically acceptable salt or ester thereof.
11. The method of claim 10 , wherein the androgenic agent is selected from the group consisting of testosterone, methyltestosterone, dehydroepiandrosterone, and testosterone undecanoate.
12. The method of claim 11 , wherein the androgenic agent is testosterone or a pharmaceutically acceptable salt or ester thereof.
13. The method of claim 1 , wherein the aromatase inhibitor is selected from the group consisting of anastrozole, exemestane, and letrozole.
14. The method of claim 13 , wherein the aromatase inhibitor is anastrozole.